Discovery of a Specific CKIP-1 Ligand using DEL

Casein kinase 2-interacting protein-1 (CKIP-1) performs a critical negative role in the regulation of bone formation. Accumulated evidence strongly supports CKIP-1 as an attractive therapeutic target in osteoporosis. As a scaffold protein lacking enzymatic activity, CKIP-1 seems to be an undruggable target, and the development of selective small molecule inhibitors targeting CKIP-1 has proven to be challenging. One potential strategy for overcoming this hurdle is to use the technique of targeted protein degradation.
In a recent study, researchers demonstrate that VHL is a suitable E3 ligase for designing PROTAC® molecules to degrade CKIP-1 in bone marrow stem cells. The authors leverage WuXi AppTec’s DNA encoded library (DEL) to successfully identify a small molecule ligand (C77) with high affinity toward CKIP-1, underscoring the potential of using VHL and C77 to develop CKIP-1-targeted PROTACs. This work illustrates the application of DEL technology in advancing PROTAC development for novel targets.
Related Content
In our latest publication, WuXi AppTec scientists introduce two new methods that utilize readily accessible aldehydes to create substituted isoxazolines...
VIEW RESOURCEDNA-encoded library (DEL) technology has been recognized as a major screening method with unique advantages for offering vast chemical diversity...
VIEW RESOURCE